About Stocosil

About company

Stocosil is a pharmaceutical company delivering next generation products that treat the double-threat of hypertension and high cholesterol. Stocosil strikes at the heart of cardiovascular disease with their lead drug product, Kubiqo —a dual-drug pill that simultaneously treats hypertension and high cholesterol, reducing risk by a dramatic 45%. Kubiqo is a fixed dose combination of olmesartan medoxomil and rosuvastatin calcium which currently does not exist in the United States. In addition to Kubiqo, Stocosil has a strong pipeline of products that will tap into a large global market and multi-billion dollar revenue potential. Stocosil boasts an impressive management team possessing significant experience in drug development.